Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.5 (
cathepsin D
)
4,130
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In
Photofrin
-mediated photodynamic therapy (PDT), cell fate can be modulated by the subcellular location of
Photofrin
. PDT triggers oxidative damage to target cells, including the methionine (Met) oxidation of proteins. Here, we developed a new Met-containing peptide enrichment protocol combined with SILAC-based quantitative proteomics, and used this approach to explore the global Met oxidation changes of proteins in PDT-treated epidermoid carcinoma A431 cells preloaded with
Photofrin
at the plasma membrane, ER/Golgi, or ubiquitously. We identified 431 Met-peptides corresponding to 302 proteins that underwent severe oxidation upon PDT and observed overrepresentation of proteins related to the cell surface, plasma membrane, ER, Golgi, and endosome under all three conditions. The most frequently oxidized Met-peptide sequence was "QAMXXMM-E/G/M-S/G-A/G/F-XG". We also identified several hundred potential
Photofrin
-binding proteins using affinity purification coupled with LC-MS/MS, and confirmed the bindings of EGFR and
cathepsin D
with
Photofrin
. The enzyme activities of both proteins were significantly reduced by
Photofrin
-PDT. Our results shed light on the global and site-specific changes in Met-peptide oxidation among cells undergoing
Photofrin
-PDT-mediated oxidative stress originating from distinct subcellular sites, and suggest numerous potential
Photofrin
-binding proteins. These findings provide new insight into the molecular targets through which
Photofrin
-PDT has diverse effects on target cells.
...
PMID:Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. 2846 86